Navigation Links
NxStage(R) Reports Third Quarter 2009 Financial Results and Raises Revenue Guidance for Fiscal 2009
Date:11/5/2009

quarter of 2008.

Gross margin improved to 25 percent in the third quarter of 2009 as compared to 16 percent in the third quarter of 2008.

Net loss for the third quarter of 2009 was $10.0 million, or ($0.22) per share. This compares to a net loss of $15.0 million, or ($0.33) per share for the third quarter of 2008, which included the negative impact of a $1.8 million change in fair value of financial instruments.

Cash and cash equivalents as of September 30, 2009 were $22.1 million. The Company's cash usage for the third quarter of 2009 was $2.4 million.

For the third quarter of 2009, the Company had an Adjusted EBITDA loss of $2.4 million, adjusted for stock-based compensation, deferred revenue recognized and other non-recurring expenses, compared with an Adjusted EBITDA loss of $7.3 million in the third quarter of 2008. These results were better than the Company's guidance for an Adjusted EBITDA loss of $3.0 to $4.0 million for the third quarter of 2009. (See the exhibits for a reconciliation of this non-GAAP measure.)

Guidance:

For the fourth quarter of 2009, the Company is forecasting revenue to be between $37.0 to $39.0 million, a net loss in the range of $8.5 to $9.5 million or ($0.18) to ($0.21) per share, and an Adjusted EBITDA loss in the range of $1.5 to $2.5 million.

Supported by its strong performance year to date in 2009, the Company now anticipates revenue for the 2009 fiscal year to be in a range of $145 to $147 million, compared with its prior guidance for revenue to be in a range of $135 to $145 million.

This release contains a non-GAAP financial measure. A reconciliation of the Company's non-GAAP financial measure to its most comparable GAAP financial measure is in the exhibits to this press release.

Conference Call:

NxStage will also host a conference call today at 9:00 a.m. Eastern Time to discuss its third qua
'/>"/>

SOURCE NxStage Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. NxStage(R) to Recognize Several Key Milestones at American Society of Nephrologys Renal Week 2007
2. Boston Business Journal Names NxStage(R) Medical Third Fastest Growing Company in Massachusetts
3. NxStage(R) to Report Third Quarter 2009 Financial Results
4. NxStage(R) Reports Significant Interim FREEDOM Study Results
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. Spherix Reports Second Quarter Earnings
7. Tapestry Reports Second Quarter 2007 Results
8. Callisto Reports on Second-Quarter 2007 Milestones
9. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... , May 29, 2015 Amgen (NASDAQ: ... two pivotal Phase 3, global, randomized, placebo-controlled trials ... treatment of secondary hyperparathyroidism (SHPT) in patients with ... met the primary endpoint, demonstrating that a greater ... achieved a greater than 30 percent reduction in ...
(Date:5/29/2015)... Pa. , May 29, 2015 ... focus of the Association for the Advancement of ... With support from AAWC,s corporate partners, ... Educational Portal on the AAWC website at ... a wound care pathway with links to various ...
(Date:5/28/2015)... 2015 Zimmer Holdings, Inc. (NYSE and SIX: ... with buyers to divest in the United ... assets, Biomet Discovery® Elbow System assets and Cobalt™ bone ... Zimmer,s pending acquisition of Biomet, Inc. ("Biomet").  ... constructively with the Bureau of Competition Staff of the ...
Breaking Medicine Technology:Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 2Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 3Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 4Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 6Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 7The Association for the Advancement of Wound Care Educates the Public 2Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 2Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 3Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 4Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 5Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 6
... Reportlinker.com announces that a new market research ... Triple Analysis: Lung Cancer, Lymphoma ... This triple analysis ... both Lung Cancer and Lymphoma and by ...
... 23, 2011 Applied Medical today announced that it ... Covidien) on May 17, 2011 in the U.S. District ... a recently issued Applied Medical trocar seal patent by ... Action No. CV 11-4203 VBF (AJWx). The patent is ...
Cached Medicine Technology:Reportlinker Adds Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis 2Reportlinker Adds Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis 3Reportlinker Adds Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis 4Reportlinker Adds Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis 5Applied Medical Sues Covidien, Asserting Recently Issued Universal Seal Trocar Patent 2
(Date:5/30/2015)... 30, 2015 Thousands of aesthetic industry ... Meeting, sponsored by the American Society for Aesthetic Plastic ... hand was Zeltiq, the parent company of one of ... With blazing growth, the one-of-a-kind device just sold ... Zeltiq is currently in the news for gaining the ...
(Date:5/30/2015)... On Thursday, May 14, the Mesothelioma ... Dr. Evan Alley both of the University of ... series. The interview was part of the series ... Drs. Simone and Alley were interviewed by the ... they discussed the mesothelioma program at the University ...
(Date:5/30/2015)... 2015 Responding to surging demand from ... experienced OGAWA products while abroad, OGAWA-engineered massage products have ... A leader in the Asian health and wellness industry ... developer and manufacturer of health and wellness equipment. ... their products, health enthusiasts in Asia and Australia, as ...
(Date:5/30/2015)... 2015 Cyclist Barry Haarde will ... the World 2015: Piles of Miles” near San ... about hemophilia and encourage individuals to support needy ... Save One Life supports nearly 1,200 impoverished children ... through direct sponsorships, scholarships and micro-enterprise grants. Hemophilia ...
(Date:5/30/2015)... (PRWEB) May 30, 2015 The iconic ... Jones, will be hosting a new segment on Medical ... aspects of medical malpractice in the health care field. ... 2014 thousands of medical malpractice suits were filed, roughly ... 50% were settled out of court, while the remaining ...
Breaking Medicine News(10 mins):Health News:Dr. Paul Vitenas Meets with Zeltiq President and CEO in Montreal 2Health News:Dr. Paul Vitenas Meets with Zeltiq President and CEO in Montreal 3Health News:Interview with Mesothelioma Experts, Drs. Simone and Alley Now Available on Demand 2Health News:Award-winning OGAWA Massage Chairs Finally Available for purchase in North America. 2Health News:Award-winning OGAWA Massage Chairs Finally Available for purchase in North America. 3Health News:Barry Haarde Cycles 4,000 Miles Across the USA for Hemophilia 2
... Drought Tolerance, DES MOINES, Iowa, Feb. 4 ... today for a three-day project review,meeting focused on ... DD ) business Pioneer-Hi-Bred, the intent of ... and private organizations in order to,help increase farm ...
... The Beryl Companies announced today the,appointment ... president of,marketing communications. In this role, she ... branding initiatives, working closely,with sales, customer relations ... extensive background in marketing communications,research and operations ...
... by more than 78% , , MONDAY, Feb. 4 (HealthDay News) ... down, a new study shows it may also ease the ... simple sugar-and-water solution will also ease parents, fears and boost ... parents to get their children vaccinated," said study author Linda ...
... - Advocacy Group Urges Russian President Vladimir Putin to Adopt a ... ... The Movement Against Cancer, a cancer,patient advocacy group in Russia, ... inadequate access for cancer,patients in Russia to innovative and effective treatments, ...
... Calif., Feb. 4 Poniard,Pharmaceuticals, Inc. (Nasdaq: ... announced that Jerry McMahon, Ph.D., chairman and CEO,will ... Investor Conference 2008 on,Monday, February 11, at 11:45 ... Dr. McMahon will provide a corporate overview, ...
... Medco Health,Solutions, Inc. (NYSE: MHS ) plans ... a press release before the market opens,on Tuesday, Feb. ... a conference call to review,the financial results, outlook and ... the live conference call via telephone:, Dial in: ...
Cached Medicine News:Health News:DuPont Hosts Meeting of Leading Plant Scientists to Improve World Agricultural Productivity 2Health News:Sugar Water Eases Pain of Infant Vaccinations 2Health News:Sugar Water Eases Pain of Infant Vaccinations 3Health News:Movement Against Cancer, a Cancer Patient Advocacy Group in Russia, Launches an Effort to Inform Russian Authorities and the Public About Inadequate Access of Innovative and Effective Cancer Treatments for Cancer Patients in Russia 2Health News:Poniard Pharmaceuticals Announces Upcoming Conference Participation 2Health News:Medco Announces Date for Fourth-Quarter and Full-Year 2007 Financial Results 2
Each handle is designed to fit a specific trephine size....
Reusable, stainless steel trephine with handle....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Medicine Products: